<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620160</url>
  </required_header>
  <id_info>
    <org_study_id>RAY1216-22-02</org_study_id>
    <nct_id>NCT05620160</nct_id>
  </id_info>
  <brief_title>Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of RAY1216 Tablets in Patients With Mild to Moderate SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Raynovent Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Raynovent Biotech Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess&#xD;
      the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2&#xD;
      infection. The total study duration is up to 28 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 12, 2022</start_date>
  <completion_date type="Anticipated">April 20, 2023</completion_date>
  <primary_completion_date type="Actual">January 19, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to sustained clinical recovery of 11 COVID-19 symptoms</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>The time from the start of treatment to the time when 11 COVID-19 symptoms get scores of 0 for three consecutive days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with severe COVID-19 disease or death</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 viral shedding time in nasopharyngeal swabs</measure>
    <time_frame>baseline, Day 4, Day 6, Day 10, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of viral load compared to the baseline</measure>
    <time_frame>baseline, Day 4, Day 6, Day 10, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical sustained remission</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in clinical recovery/remission</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1359</enrollment>
  <condition>Mild to Moderate COVID-19</condition>
  <arm_group>
    <arm_group_label>RAY1216</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 400mg RAY1216 tablet orally three times daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received 400mg placebo orally three times daily for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAY1216</intervention_name>
    <description>RAY1216（tablet）</description>
    <arm_group_label>RAY1216</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo （tablet）</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants who provide written informed consent before the trial, and fully&#xD;
             understand the trial content, process and possible adverse reactions.&#xD;
&#xD;
          2. Participants who are willing and able to comply with the protocol for treatment plan,&#xD;
             virological testing, laboratory testing and other study procedures.&#xD;
&#xD;
          3. Male or female participants aged 18-75 (including 18 and 75 years old).&#xD;
&#xD;
          4. Confirmed SARS-CoV-2 infection 120 hours prior to randomization.&#xD;
&#xD;
          5. Initial onset of COVID-19 symptoms/signs within 48 hours before randomization.&#xD;
&#xD;
          6. Fertile participants must agree to take effective contraceptive measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe or critical COVID-19 who currently require hospitalization, or&#xD;
             patients who are expected to develop into severe or critical disease and require&#xD;
             hospitalization within 48h after randomization.&#xD;
&#xD;
          2. Difficulty swallowing or a history of gastrointestinal diseases that seriously affect&#xD;
             drug absorption.&#xD;
&#xD;
          3. Active liver disease, or obvious abnormal liver function (ALT or AST ≥ 3ULN, or total&#xD;
             bilirubin ≥ 2ULN).&#xD;
&#xD;
          4. WBC &gt;1ULN, or NEU &lt;0.5ⅹ109/L.&#xD;
&#xD;
          5. Receiving dialysis or have known moderate to severe renal impairment&#xD;
             (eGFR&lt;60mL/min/1.73m2).&#xD;
&#xD;
          6. Other suspected or confirmed systemic infections.&#xD;
&#xD;
          7. Current or expected use of strong CYP3A4 inducers, inhibitors or medications that are&#xD;
             highly dependent on CYP3A4 or CYP2C19 for clearance.&#xD;
&#xD;
          8. Prior or anticipated receipt of any vaccine within 28 days prior to enrollment and&#xD;
             during study period.&#xD;
&#xD;
          9. Use of antivirals against SARS-CoV-2 within 7 days prior to enrollment.&#xD;
&#xD;
         10. Weight≤40kg.&#xD;
&#xD;
         11. Pregnant, lactating women or those with a positive pregnancy test (sterilized or&#xD;
             postmenopausal women may not have a pregnancy test).&#xD;
&#xD;
         12. Previous administration with any investigational drug within 3 months before the study&#xD;
             drug administration.&#xD;
&#xD;
         13. Participants who are judged by the investigator to be unsuitable to participate in&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>March 28, 2023</last_update_submitted>
  <last_update_submitted_qc>March 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

